Overview
TB-500 is an identity-sensitive name. FDA describes it as the LKKTETQ thymosin beta-4 fragment, whereas this catalog’s source comment refers to full-length thymosin beta-4 and its descriptive copy refers to a fragment6.
Until the dispensing pharmacy confirms sequence and active ingredient, the evidence tier remains conservative. All parent-molecule research below is explicitly labeled and is not treated as direct validation of the catalog product1,3,5,6.
Parent peptide & fragment distinction
Full-length thymosin beta-4 is a naturally occurring actin-associated peptide involved in cellular injury responses. Research examined its effects on endothelial cells, skin wounds and other tissue models1,2.
The fragment shares part of that sequence but is chemically and pharmacologically distinct. The presence of a shared motif does not establish equivalent exposure, activity or clinical effect1,6.
Mechanism of action
The full-length peptide binds G-actin and has a broad experimental record involving cell migration, matrix enzymes and repair-related biology. Much commercial TB-500 discussion derives from this parent-molecule literature1,2.
Endothelial-cell assays reported a 4–6-fold migration increase over medium-only controls with full-length thymosin beta-4. That is an in-vitro migration result, not a rate of human injury recovery2.
- 1Binds actinThymosin β4 binds G-actin, controlling the cytoskeletal remodelling that lets cells crawl into damaged tissue1.
- 2Mobilizes blood-vessel cellsIt increased the directional migration of human endothelial cells four- to six-fold, a first step in new vessel formation2.
- 3Clears a pathThymosin β4 also raised production of matrix metalloproteinases, enzymes that open the basement membrane during angiogenesis2.
- 4Closes woundsIn normal, aged, diabetic and steroid-treated animals, it accelerated healing of full-thickness skin wounds4.
- G-actin binding
- Cell migration
- Endothelial repair
- Matrix remodelling
- Wound-response biology
Human parent-peptide studies
A topical full-length thymosin beta-4 study randomized 73 patients with venous ulcers. It reported acceptable tolerability and an exploratory suggestion of accelerated healing, in the setting of local wound management3.
A healthy-volunteer trial tested intravenous full-length thymosin beta-4 with safety and pharmacokinetic measures. Neither study establishes efficacy of the fragment or routine subcutaneous sports-recovery use3,5.
Faster wound closure4
Thymosin β4 accelerated dermal healing in rats and mice, including diabetic, aged and steroid-treated models.
In two phase 2 trials of stasis and pressure ulcers, it sped healing by almost a month in patients who healed.
Angiogenesis2
Endothelial cells migrated four- to six-fold more and produced more matrix-remodelling enzymes.
Human safety data5
Single and 14-day intravenous dosing from 42 to 1,260 mg was well tolerated in a placebo-controlled study, with no dose-limiting toxicity.
Repair models & translation
Full-length thymosin beta-4 reviews describe animal dermal-healing experiments and cellular migration biology. These provide a rationale for parent-peptide research rather than a proven outcome for TB-5001,4.
Route and molecule both matter: topical wound exposure, intravenous full-length exposure and a systemic fragment preparation ask different questions. A combination with another peptide adds an additional untested formulation layer3,5,6.
Safety & identity uncertainty
FDA states that human exposure data for the TB-500 fragment have not been identified and flags aggregation, impurities and immunogenicity concerns. Parent-peptide tolerability cannot remove those uncertainties6.
The ambiguity must be resolved by the dispensing pharmacy before assumptions about sequence, molecular weight, route or dosing. No exact sequence or half-life is assigned to this catalog entry because its identity is not consistently documented6.
- Confirm whether the active ingredient is full-length thymosin beta-4 or a fragment before use.
- FDA reports no identified human exposure data for the TB-500 fragment [6].
- Potential aggregation, impurities and immunogenicity remain concerns [6].
- Full-length topical or intravenous tolerability does not establish fragment safety.
Supply, storage & administration
Confirm the active ingredient first. The cited clinical preparations were topical or intravenous full-length thymosin beta-4; they do not define a routine subcutaneous TB-500 protocol3,5. Lyophilized or liquid status, diluent, storage and route must come from the pharmacy’s actual product label.
The catalog specifies vial content, not a verified final formulation or storage specification. A lyophilized preparation requires the pharmacy-specified compatible diluent; a ready-to-use liquid does not. Follow the dispensing label for refrigeration, light protection and the beyond-use date, and use aseptic technique with a new sterile needle and syringe7. Dosing is set by your provider.
Questions
Is TB-500 the same as thymosin beta-4?
The name is used inconsistently. FDA describes a fragment; the catalog also contains a full-length source comment. Ask the pharmacy for the actual identity.
Why show full-length studies?
They explain the borrowed scientific rationale, with explicit limits on applying them to a fragment.
TB-500 or BPC-157?
The parent thymosin literature emphasizes actin-associated cell movement; BPC-157 has fibroblast and vascular-signalling work. Neither establishes broad recovery efficacy for these compounded products.
Does the ulcer trial prove injectable healing?
No. It tested a topical full-length preparation in a defined clinical setting.
Why omit sequence and half-life?
The catalog identity is ambiguous; assigning parent or fragment values would imply certainty that is not present.
References
- 1.Review
Goldstein AL, Hannappel E, Sosne G, et al.. Expert opinion on biological therapy, 2012. PMID 22074294
Reviews thymosin β4’s actin-binding, cell-migration and regenerative biology.
- 2.Cell study
Malinda KM, Goldstein AL, Kleinman HK. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 1997. PMID 9194528
Full-length thymosin beta-4 increased endothelial migration 4–6-fold in vitro and affected matrix enzymes.
- 3.Phase 2 RCT
The effect of thymosin treatment of venous ulcers. (opens in a new tab)
Guarnera G, DeRosa A, Camerini R, et al.. Annals of the New York Academy of Sciences, 2010. PMID 20536470
A topical full-length thymosin beta-4 study randomized 73 venous-ulcer patients and reported exploratory healing findings.
- 4.Review
Treadwell T, Kleinman HK, Crockford D, et al.. Annals of the New York Academy of Sciences, 2012. PMID 23050815
Reviews full-length dermal-healing models and early topical clinical research.
- 5.Randomized trial
Ruff D, Crockford D, Girardi G, et al.. Annals of the New York Academy of Sciences, 2010. PMID 20536472
A healthy-volunteer intravenous study assessed full-length thymosin beta-4 tolerability and pharmacokinetics.
- 6.Guidance / label
U.S. Food and Drug Administration. Regulatory guidance / prescribing information, 2026.
FDA describes limited human safety information and relevant compounding risks for the thymosin beta-4 fragment LKKTETQ / TB-500.
- 7.Guidance / label
Preventing Unsafe Injection Practices (opens in a new tab)
Centers for Disease Control and Prevention. Regulatory guidance / prescribing information, 2024.
Use aseptic technique and a new sterile needle and syringe; opened multi-dose vials generally have a 28-day discard window unless the manufacturer specifies otherwise, never beyond original expiration.
Research summaries are educational and describe published studies, many in animal or cell models. They are not claims that this product treats any condition. Compounded medications are prepared by a licensed 503A pharmacy for individual patients and are not FDA-approved. Statements on this site have not been evaluated by the FDA. Products are dispensed only after review by a licensed provider. This site does not provide medical advice; talk to your provider before starting any therapy.